Group One Trading
HBIO icon

Group One Trading’s Harvard Bioscience HBIO Stock Holding History

Group One Trading’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7K Buy
2,200
+1,980
+900% +$11.1K ﹤0.01% 6340
2025
Q4 		$1.47K Buy
+220
New +$1.3K ﹤0.01% 7632
2025
Q2 		– Sell
-60
Closed -$340 – 8204
2025
Q1 		$340 Hold
60
– – ﹤0.01% 7331
2024
Q4 		$1.27K Buy
+60
New +$1.38K ﹤0.01% 6847
2023
Q4 		– Sell
-100
Closed -$4.3K – 7694
2023
Q3 		$4.3K Buy
+100
New +$4.61K ﹤0.01% 6772
2022
Q1 		– Sell
-80
Closed -$6K – 8275
2021
Q4 		$6K Buy
+80
New +$5.69K ﹤0.01% 7575
2015
Q4 		– Sell
-950
Closed -$36K – 4863
2015
Q3 		$36K Hold
950
– – ﹤0.01% 3732
2015
Q2 		$54K Buy
+950
New +$54.1K ﹤0.01% 3492
2014
Q3 		– Sell
-220
Closed -$10K – 5267
2014
Q2 		$10K Sell
220
-200
-48% -$8.4K ﹤0.01% 4509
2014
Q1 		$20K Buy
420
+120
+40% +$5.46K ﹤0.01% 4236
2013
Q4 		$14K Sell
300
-5,939
-95% -$259K ﹤0.01% 4438
2013
Q3 		$249K Buy
6,239
+6,107
+4,627% +$240K ﹤0.01% 2188
2013
Q2 		$5K Buy
+132
New +$5.05K ﹤0.01% 4679

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's HBIO Position: Q1 2026 in Review

Group One Trading reduced its Harvard Bioscience (HBIO) stake by 14% in Q1 2026, selling an estimated $2.06K and leaving 2,182 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6346.

Group One Trading first reported a position in HBIO in Q2 2013 and has held it in 13 quarters since. The position peaked at $430K in Q3 2013. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Group One Trading held 2,182 shares of Harvard Bioscience worth $10.6K as of Q1 2026.
  • Group One Trading sold 369 Harvard Bioscience shares in Q1 2026, an estimated $2.06K.
  • Harvard Bioscience made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6346 holding.
  • Group One Trading first reported a position in Harvard Bioscience in Q2 2013 and has held it in 13 quarters since.
  • Group One Trading's Harvard Bioscience position peaked at $430K in Q3 2013.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.